毒性
前列腺癌
医学
癌症
前列腺
癌症研究
肿瘤科
内科学
作者
Nour Shobaki,Khatuna Gabunia,Decheng Song,Ting-Jia Fan,Fang Liu,Mei Qing Ji,Andrew J. Rech,Mansi Deshmukh,Seth Eisenberg,Ethan Sun,Huijun Wei,John Scholler,Carl H. June
出处
期刊:
日期:2024-11-01
卷期号:: A367-A367
标识
DOI:10.1136/jitc-2024-sitc2024.0318
摘要
Background Metastatic castration-resistant prostate cancer (mCRPC) represents the lethal phase of advanced prostate cancer and is resistant to most immune therapies, including checkpoint immunotherapy. While chimeric antigen receptor (CAR) T cell therapy is a promising approach to treat mCRPC, dose-dependent and/or antigen-dependent toxicity of validated CAR T cell targets, such as prostate-specific membrane antigen (PSMA), are still a challenge. Many antigens expressed on mCRPC, including PSMA, are also found on critical normal tissues, potentially causing on-target/off-tumor toxicities and lowering the therapeutic index. Our clinical partners here at Penn recently reported results from a first-in-human phase 1 clinical trial (NCT03089203) that assessed the safety and feasibility of PSMA-targeted CAR T cells in mCRPC. Despite the encouraging dose-dependent efficacy of PSMA-CAR T cells observed in this trial, treatment responsiveness strongly correlated with increased toxicity evidenced by cytokine release syndrome (CRS), macrophage activation syndrome (MAS, i.e., immune effector cell-associated hemophagocytic lymphohistiocytosis-like Syndrome or IEC-HS), and immune effector cell-associated neurotoxicity syndrome (ICANS). Similar results were reported from another phase 1 multi-center trial that tested the safety of PSMA-CAR T cells in patients with advanced mCRPC (Tm-PSMA-01; NCT04227275). Methods Considering that human PSMA (huPSMA) surface expression is not restricted to the prostate, we developed a novel physiologically relevant immunocompetent mouse model, established in our colony, to evaluate the on-target/off-tumor toxicities of huPSMA-targeted therapies. Specifically, we used huPSMA knock-in (KI) mice in which huPSMA expression is driven by the endogenous mouse PSMA promoter. Results Initial evaluation of huPSMA in huPSMA-KI mice found high huPSMA expression in the kidneys, and we are currently evaluating huPSMA expression in other organs. In this model, we accurately identified PSMA-CAR T cell therapeutic toxicity in vivo and found that treatment can be lethal at doses used in these mice as early as day five post treatment. A full veterinary histopathological examination correlated neurotoxicity and myeloid hyperplasia as likely causes of animal death. This was evidenced by the necrotic and degenerative changes affecting the brain and spinal cord, as well as myeloid hyperplasia in the bone marrow. These observed lethal toxicities were reminiscent of the ICANS and MAS (IEC-HS) observed in clinical trials with PSMA-targeted therapies. Conclusions Our findings highlight the utility of huPSMA-KI mice as a model for on-target/off-tumor toxicity of PSMA-targeting therapies. This may provide a foundation for the design of future clinical trials to provide safe and effective treatments for patients with mCRPC. Acknowledgements Thanks to the Comparative Pathology Core (CPC) at PennVet for performing complete pathological evaluation, immunohistochemistry staining and RNAScope. Thanks to the Pathology Core at CHOP for performing immunohistochemistry staining. Thanks to Biocytogen for providing huPSMA-KI mice.
科研通智能强力驱动
Strongly Powered by AbleSci AI